Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DBVT
stocks logo

DBVT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.74M
+211.45%
-0.371
+61.43%
875.46K
+9.51%
-0.400
+54.1%
875.46K
-40.36%
-0.491
+57.94%
Estimates Revision
The market is revising Upward the revenue expectations for DBV Technologies S.A. (DBVT) for FY2025, with the revenue forecasts being adjusted by 64.58% over the past three months. During the same period, the stock price has changed by 45.55%.
Revenue Estimates for FY2025
Revise Upward
up Image
+64.58%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+126.79%
In Past 3 Month
Stock Price
Go Up
up Image
+45.55%
In Past 3 Month
Wall Street analysts forecast DBVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBVT is 20.00 USD with a low forecast of 19.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast DBVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBVT is 20.00 USD with a low forecast of 19.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.050
sliders
Low
19.00
Averages
20.00
High
21.00
Current: 13.050
sliders
Low
19.00
Averages
20.00
High
21.00
Guggenheim
initiated
$35
2025-12-03
New
Reason
Guggenheim
Price Target
$35
2025-12-03
New
initiated
Reason
As previously reported, Guggenheim initiated coverage of DBV Technologies with a Buy rating and $35 price target, citing a positive view of the company's unique epicutaneous immunotherapy approach to combat peanut allergy in the pediatric population and the potential to capitalize on this "large untapped" peanut allergy market. Palforzia, marketed by Stallergenes Greer, is currently the only approved immunotherapy in peanut allergy, but it comes with noteworthy disadvantages, and DBV aims to revitalize the peanut allergy immunotherapy space by introducing a more convenient, safe, and effective alternative to an oral therapy with its Viaskin peanut patch, the analyst tells investors.
Guggenheim
NULL -> Buy
initiated
$35
2025-12-03
New
Reason
Guggenheim
Price Target
$35
2025-12-03
New
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of DBV Technologies with a Buy rating and $35 price target.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$16 -> $20
2025-10-29
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$16 -> $20
2025-10-29
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on DBV Technologies to $20 from $16 and keeps a Buy rating on the shares following the Q3 report. The firm says that with the VITESSE Phase 3 data expected in Q4 and dual application filings planned in 2026 for children and toddlers, DBV is positioned to deliver the first broadly accessible epicutaneous immunotherapy. A positive VITESSE readout "could unlock both regulatory momentum and warrant-linked capital," extending DBV's cash runway into commercialization, the analyst tells investors in a research note.
Goldman Sachs
Rajan Sharma
reinstated
$7.25
2025-05-29
Reason
Goldman Sachs
Rajan Sharma
Price Target
$7.25
2025-05-29
reinstated
Reason
Citizens JMP
Outperform
maintain
$15 -> $21
2025-05-27
Reason
Citizens JMP
Price Target
$15 -> $21
2025-05-27
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on DBV Technologies to $21 from $15 and keeps an Outperform rating on the shares. Xolair's food allergy launch has more than 50K patients on drug within the first year despite some key hindrances, which may be limiting its use in Viaskin Peanut's target 1-7 year old population, the analyst tells investors in a research note. The firm sees the Phase 3 VITESSE data in 4-7 year olds in Q4 as the next key catalyst for shares.
Citizens Capital Markets
Jonathan Wolleben
Buy
Reiterates
$10
2025-03-04
Reason
Citizens Capital Markets
Jonathan Wolleben
Price Target
$10
2025-03-04
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Dbv Technologies SA (DBVT.O) is -9.69, compared to its 5-year average forward P/E of -3.77. For a more detailed relative valuation and DCF analysis to assess Dbv Technologies SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.77
Current PE
-9.69
Overvalued PE
-1.79
Undervalued PE
-5.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.63
Current EV/EBITDA
-2.77
Overvalued EV/EBITDA
-0.03
Undervalued EV/EBITDA
-3.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
47.94
Current PS
83.40
Overvalued PS
75.58
Undervalued PS
20.31
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 2153.01% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 2153.01% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

DBVT News & Events

Events Timeline

(ET)
2025-11-12
05:48:38
DBV Technologies reports completion of final patient visit in VITESSE trial
select
2025-11-03 (ET)
2025-11-03
17:19:05
DBV Technologies names Kevin Trapp as chief commercial officer
select
2025-10-28 (ET)
2025-10-28
16:30:40
DBV Technologies announces Q3 GAAP EPS of 24 cents, falling short of consensus estimate of 29 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-19Benzinga
RFK Jr. Dismisses Early Exposure Theory for Increasing Peanut Allergies, Attributes Cause to Aluminum-Based Vaccines

  • Kennedy's Stance on Peanut Allergies: Health and Human Services Secretary Robert F. Kennedy Jr. challenges the prevailing view that delayed peanut introduction is the main cause of rising peanut allergies, suggesting that aluminum in vaccines may be a contributing factor.

  • DBV Technologies' Progress: DBV Technologies is advancing its VIASKIN Peanut patch for treating peanut allergies, with the completion of the Phase 3 VITESSE trial, and plans to release topline data in the fourth quarter of 2025.

  • Rising Peanut Allergy Statistics: The prevalence of peanut allergies in children has increased significantly over the past 25 years, from 0.5% in 1997 to approximately 2% today, according to the National Institutes of Health.

  • Impact of Early Introduction Guidelines: Recent research indicates that early introduction of peanut products to infants, especially those at high risk, has led to a notable decline in peanut allergies, supporting revised feeding guidelines initiated in 2015 and expanded in 2017.

[object Object]
Preview
4.5
11-12Benzinga
LightPath Technologies Shares Rise 7%; Check Out 20 Stocks Making Moves in Premarket Trading

  • LightPath Technologies Performance: LightPath Technologies Inc. shares rose 6.8% in pre-market trading after reporting a quarterly loss of 7 cents per share, which was better than the expected 9-cent loss, alongside revenue of $15.05 million exceeding estimates.

  • Notable Gainers: Salarius Pharmaceuticals surged 170% after announcing pricing for its public offering, while Kandal M Venture and Amaze Holdings also saw significant pre-market gains of 70.4% and 68.4%, respectively.

  • Significant Losers: MSP Recovery Inc. dropped 18.2% in pre-market trading following a previous surge, with other notable declines including Aspire Biopharma and Rain Enhancement Technologies, which fell 16.5% and 14.3%, respectively.

  • Market Overview: The article provides a snapshot of various stocks moving in pre-market trading, highlighting both gainers and losers, along with specific percentage changes in their share prices.

[object Object]
Preview
9.0
11-12NASDAQ.COM
DBV Technologies Set to Release VITESSE Phase 3 Trial Data for VIASKIN Peanut Patch in Q4

  • Completion of Phase 3 Trial: DBV Technologies has completed the final patient visit in its Phase 3 VITESSE clinical trial for the VIASKIN Peanut patch, aimed at treating peanut allergies in children aged 4 to 7 years.

  • Trial Details: The VITESSE trial is the largest intervention study for peanut allergies in this age group, involving 654 children across multiple countries, and assesses the safety and efficacy of the patch using epicutaneous immunotherapy technology.

  • Safety Monitoring: No new safety concerns or adverse events have been reported so far, and the company continues to monitor safety data as it prepares for the next steps.

  • Future Expectations: DBV Technologies anticipates announcing topline results in Q4 2025, which could lead to regulatory submissions and wider access to the treatment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Dbv Technologies SA (DBVT) stock price today?

The current price of DBVT is 13.05 USD — it has increased 0.46 % in the last trading day.

arrow icon

What is Dbv Technologies SA (DBVT)'s business?

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

arrow icon

What is the price predicton of DBVT Stock?

Wall Street analysts forecast DBVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DBVT is 20.00 USD with a low forecast of 19.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Dbv Technologies SA (DBVT)'s revenue for the last quarter?

Dbv Technologies SA revenue for the last quarter amounts to 2.77M USD, increased 158.77 % YoY.

arrow icon

What is Dbv Technologies SA (DBVT)'s earnings per share (EPS) for the last quarter?

Dbv Technologies SA. EPS for the last quarter amounts to -0.24 USD, decreased -25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Dbv Technologies SA (DBVT)'s fundamentals?

The market is revising Upward the revenue expectations for DBV Technologies S.A. (DBVT) for FY2025, with the revenue forecasts being adjusted by 64.58% over the past three months. During the same period, the stock price has changed by 45.55%.
arrow icon

How many employees does Dbv Technologies SA (DBVT). have?

Dbv Technologies SA (DBVT) has 108 emplpoyees as of December 05 2025.

arrow icon

What is Dbv Technologies SA (DBVT) market cap?

Today DBVT has the market capitalization of 522.54M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free